In a nutshell This multicenter phase 3 clinical trial will test the effectiveness of nivolumab (Opdivo) after surgery and chemotherapy in stage 1b to 3a non-small cell lung cancer (NSCLC). The primary outcome will be measured by the length of time the patient survives without signs of the cancer and the overall survival rate for up to 10...
Read More
In a nutshell This paper compared the use of carfilzomib (Kyprolis) and bortezomib (Velcade) in the treatment of multiple myeloma. This study concluded that carfilzomib was associated with a reduced risk of death compared with bortezomib. Some background Multiple myeloma is a cancer of the plasma cells. New treatments have led to longer survival...
Read More
In a nutshell This study examined the safety and effectiveness of durvalumab (Imfinzi) in patients with stage III non-small cell lung cancer. This study concluded that durvalumab delayed time to disease progression. Some background Chemotherapy and radiation are the standard treatment options for stage III non-small cell lung cancer (NSCLC, cancer...
Read More
In a nutshell The aim of this study was to examine the effect of preventative fungal treatment in acute leukemia patients with different risk factors. Researchers identified a number of risk factors that can increase the incidence of a severe fungal infection after chemotherapy. Preventative fungal treatment for patients undergoing primary chemotherapy...
Read More
In a nutshell This study examined infection rates after autologous stem cell transplantation in multiple myeloma patients. 1.2% in-hospital deaths were recorded in this study. All were caused by an infection following the stem cell transplant. Some background Autologous stem cell transplantation after high-dose chemotherapy has resulted in...
Read More
In a nutshell This phase 2 clinical trial will test the safety and effectiveness of polatuzumab vedotin with obinutuzumab (Gazyva) and venetoclax (Venclexta) in patients with relapsed or refractory follicular lymphoma (FL) or rituximab (Rituxan) with polatuzumab vedotin and venetoclax in patients with relapsed or refractory diffuse large B-cell...
Read More
In a nutshell This report summarized updates made to the guidelines for treatment of HER2-positive breast cancer with adjuvant chemotherapy and targeted therapy. Some background Adjuvant chemotherapy (treatment after surgery) is often used to prevent cancer recurrence. Chemotherapy involves agents that work to kill cancer cells in the body....
Read More
In a nutshell The aim of this study was to determine the effect of biomarkers to tailor therapy in advanced prostate cancer in patients receiving abiraterone (Zytiga) treatment. The authors concluded that alkaline phosphatase (ALP- protein elevated in the blood), lactate dehydrogenase (LDH – protein involved in tumor growth) and prostate...
Read More
In a nutshell This study examined the safety and effectiveness of elotuzumab (Empliciti) for relapsed multiple myeloma. Researchers concluded that elotuzumab combined with lenalidomide (Revlimid) and dexamethasone was safe and effective at improving treatment outcomes for relapsed multiple myeloma. Some background Standard...
Read More
In a nutshell The aim of this study was to determine whether the neutrophil to lymphocyte ratio (NLR) can be used to determine outcome in CRPC patients treated with enzalutamide (Xtandi). It was concluded that NLR could be used to predict the outcome for CRPC patients treated with enzalutamide. Some background Treatment for metastatic...
Read More
In a nutshell This study investigated whether metronomic chemotherapy with oral vinorelbine (Navelbine) and capecitabine (Xeloda) was effective in treating patients with advanced HER2-negative breast cancer (BC). This form of treatment was found to be safe and effective for this patients group. Some background Metronomic chemotherapy is a form of...
Read MoreIn a nutshell This study investigated ovarian function recovery (OFR) after chemotherapy-induced amenorrhea (absence of menstruation) in women aged 40-49 after 2 years of aromatase inhibitor (AI) therapy. The study concluded that a large number of women with chemotherapy-induced amenorrhea recover ovarian function during AI therapy. Some...
Read More
